A new study found that people seeking emergency care for hallucinogen use were at a 2.6-fold higher risk of death within 5 years compared to the general population. The increased risk was highest among individuals with medical comorbidities and those from low-income neighborhoods.
The Texas Tech University Health Sciences Center is conducting a randomized controlled trial to investigate the effectiveness of calcium and vasopressin in treating severely injured patients who experience significant blood loss. The study, known as CAVALIER, will enroll approximately 1,050 participants aged 18-90.
Scientists have identified a new target to prevent cold sores by understanding how the herpes virus triggers its own immune response. The discovery has important implications for genital herpes caused by the same virus, with potential treatments in development.
Scientists have identified key corneal neurons involved in sensitivity and developed an experimental model to study nerve regeneration. The Ocular Neurobiology laboratory is participating in the RESTORE VISION project, which aims to improve eye health and quality of life for those affected by rare eye diseases.
Researchers at UCSF have discovered that human lung tissue contains hematopoietic stem cells (HSCs) capable of producing red blood cells, platelets, and immune cells. The finding suggests the lungs could be a potent source for life-saving stem cell transplants, particularly for patients with leukemia.
A nasal spray being tested for Alzheimer's disease could also reduce neuroinflammation in traumatic brain injury, according to a Mass General Brigham-led study. The treatment modulates the immune response, reducing anxiety, cognitive decline, and improving motor skills in mouse models of TBI.
The review delves into genetic, epigenetic, and molecular mechanisms driving tumor metastasis, highlighting the roles of chromosomal instability, epigenetic modifications, and tumor microenvironment interactions. It also discusses the impact of specific genetic mutations and RNA modifications on metastatic behavior.
Researchers have discovered that commonly prescribed medications can disrupt sterol biosynthesis in developing brains, potentially affecting neural development and function. The study highlights the need for reevaluating medication safety during pregnancy and early childhood.
Emerging targeted therapies specifically targeting PIK3CA mutations show promise in preclinical and clinical trials, selectively inhibiting mutant PI3Kα without affecting normal PI3K activity. These novel treatments aim to overcome limitations of existing treatments by improving patient outcomes.
Researchers found that cytomegalovirus infection significantly worsens necrotizing enterocolitis in mouse models, triggering inflammation and disrupting energy production. The study provides insight into the underlying mechanisms of NEC and may lead to the development of new treatments for this devastating condition.
Dermatology researchers have identified a novel skin disease in a male patient with erythroderma, a rare and severe inflammation that causes widespread redness and scaling. Targeted treatment with biologic inhibitors reversed symptoms, providing a promising diagnostic tool for precision-medicine.
US outpatient prescriptions for ivermectin and hydroxychloroquine increased significantly during the COVID-19 pandemic, with usage being three times higher among adults aged 65 and older. The study's findings highlight the need for policy reforms to combat misinformation and mistrust in scientific institutions.
Dr. Gordon Keller's groundbreaking research on directed differentiation of human pluripotent stem cells has illuminated the path to transforming human health. His lab's world-first discovery and pioneering efforts have pushed the boundaries of what is possible, offering hope for regenerating heart, liver, and blood cells.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
A new method combines traditional histopathology with spatial transcriptomics data to improve understanding of chronic kidney disease lesions at the cellular and molecular levels. This approach has the potential to identify new biomarkers and therapeutic strategies for patients.
Researchers developed novel antibiotic BTZ-043 to target drug-resistant tuberculosis. The study showed that BTZ-043 effectively penetrates TB lesions and accumulates there in high concentrations, making it a promising treatment option for TB patients.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
A preclinical trial has uncovered how beta-glucan can 'reprogram' immune cells to prevent lung inflammation and reduce the risk of illness and death from influenza. The study's findings highlight beta-glucan as a promising therapy for influenza and other emerging viral pathogens.
A team of researchers from the University of Arizona College of Medicine – Tucson found that an FDA-approved osteoporosis treatment, risedronate, can correct a gene mutation and normalize heart function in animal models. The study provides hope for treating other rare diseases using precision treatments tailored to individual mutations.
Researchers created optimized DNA hydrogels with fewer nucleic acids, achieving efficient and sustained drug release. The new hydrogel units showed prolonged persistence of at least 168 hours post-administration in mice, contributing to anti-tumor effects.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.
A study comparing hybrid closed-loop and open-loop systems in young people with type 1 diabetes found that hybrid closed-loop systems offered improved long-term blood sugar values, a lower risk of hypoglycemic coma, but a higher rate of diabetic ketoacidosis. The results suggest that hybrid closed-loop therapies may be beneficial for i...
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.
A study investigates the efficacy of EFC as a potential treatment for RA, showing anti-inflammatory effects on fibroblast-like synoviocytes and alleviating disease severity in animal models. The findings highlight the therapeutic potential of PDIs in RA management.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
Groundbreaking progress in TB vaccine development and therapeutic innovations offer hope to curb the disease's devastating impact, with multi-antigen vaccines and mRNA-based platforms showing promise.
Researchers found that glioblastoma stem cells are co-localized with myeloid-derived suppressor cells, promoting tumor growth and aggressiveness. The study identified key molecules, such as IL-6 and IL-8, that attract and activate MDSCs, providing new potential therapeutic targets.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
Researchers studied whether transcranial direct current stimulation could enhance constraint-induced movement therapy for post-stroke motor recovery. The study found no significant improvement in motor skills, despite using three doses of electrical stimulation on 129 stroke survivors. Future trials aim to address limitations and impro...
Researchers successfully reversed existing inguinal hernias in male mice using an anti-estrogen drug, restoring their anatomy without surgery. Human tissue samples also showed identical molecular markers as in the mouse model, suggesting a promising treatment target for inguinal hernia repair.
Researchers used AI to find adalimumab as potential treatment for iMCD, a rare disease with poor survival rate and few treatment options. The treatment has shown promising results in saving the life of a patient who was on hospice care.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
A new study led by UCL researchers has found that the GLP-1 drug exenatide has no positive impact on movement, symptoms, or brain imaging in people with Parkinson's disease. The trial involved 194 participants and ran for 96 weeks, with no benefits shown in any of these areas.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
PairMap overcomes limitations of traditional methods by introducing intermediate compounds to predict binding affinities with high accuracy. The approach minimizes calculation errors, improves convergence, and reduces computational costs for complex transformations.
Researchers from Japan found that organizational strategies, third-wave techniques, and problem-solving techniques are the most effective components of cognitive–behavioral therapy in treating ADHD. These approaches can help improve planning, prioritization, organization, emotional regulation, and stress management.
The American College of Physicians recommends preventing episodic migraines with monotherapy, including beta-adrenergic blockers and antiseizure medications. However, a comparative effectiveness systematic review found no significant differences in clinical net benefit among treatments.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
A global study published in JACC found that secondary prevention medications for cardiovascular diseases are underused worldwide, with little improvement over time. Medication use varied by country income level, with lower rates in low-income countries.
Researchers have identified ALPK2 as a potential therapeutic target for treating heart failure with preserved ejection function (HFpEF). The enzyme is believed to prevent stiff heart conditions through regulating the TPM1 gene. This discovery offers new hope for developing treatment options targeting ALPK2.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
Researchers at Rice University's Synthesis X Center and MD Anderson Cancer Center are developing a light-induced brain delivery platform to improve drug delivery across the blood-brain barrier for treating brain metastasis. The goal is to enhance survival rates and transform the standard of care for this deadly form of cancer.
A new trial will test whether taking HMB can improve patients' physical function and quality of life. The BOOST study aims to recruit 124 patients with cirrhosis and measure its effects on liver disease, mental wellbeing, and physical function over 24 weeks.
The collaboration aims to develop advanced 3D mini-brain models for replicating human brain architecture, enabling researchers to explore neurological diseases and screen drug candidates. The platform offers a high-throughput screening method for rapid testing of potential drug candidates.
A team of scientists developed a computational design tool called SPaDES to create new membrane receptors that outperform natural counterparts. The new receptors were designed by optimizing water-mediated interactions, resulting in higher stability and signaling efficiency.
A cohort study found that insurance plan type and structure play a crucial role in determining access to semaglutide for adults with obesity. The findings suggest that targeted interventions at the insurance level could improve equity in obesity treatment access.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
A new study published in Cell reveals significant differences in the immune response of children and adults to cancer, with potential implications for targeted therapies. The research shows that children's tumours are generally less inflammatory and have fewer mutations, making them appear less foreign to their immune system.
A new study demonstrates how fluorescent cholesterol probes can visualize cholesterol in live cells, revealing its role in amyloid plaque formation and cellular signaling. The novel probes have the potential to enhance our understanding of how cholesterol imbalances contribute to neurodegenerative disorders.
Researchers found that inhibiting protein RSK1 reduces inflammation and stops progression of blood cancers like myeloproliferative neoplasms and acute myeloid leukemia. The RSK1 inhibitor is already in clinical trials for breast cancer and shows promise as a treatment for blood cancers.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.